InMed Pharmaceuticals (INM) Long-Term Deferred Tax (2020 - 2023)

InMed Pharmaceuticals has reported Long-Term Deferred Tax for 4 years, with the latest figure at $21.0 million in Q2 2023.

• For the quarter ending Q2 2023, Long-Term Deferred Tax rose 12.13% year-over-year to $21.0 million; the trailing twelve-month figure through Jun 2023 stood at $21.0 million (up 12.13% YoY), and the FY2023 full-year result was $21.0 million, up 12.13% from the prior year.
• Long-Term Deferred Tax for Q2 2023 stood at $21.0 million, up from $18.8 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $21.0 million in Q2 2023, with the low at $287874.0 in Q2 2020.
• Historically, Long-Term Deferred Tax has averaged $13.5 million across 4 years, with a median of $16.4 million in 2021.
• Annual changes were most pronounced in 2021 — Long-Term Deferred Tax surged 4752.62% — and 2023, when it advanced 12.13%.
• InMed Pharmaceuticals' Long-Term Deferred Tax stood at $287874.0 in 2020, then surged by 4752.62% to $14.0 million in 2021, then jumped by 34.25% to $18.8 million in 2022, then rose by 12.13% to $21.0 million in 2023.
• The last three Long-Term Deferred Tax figures came in at $21.0 million (Q2 2023), $18.8 million (Q2 2022), and $14.0 million (Q2 2021), per Business Quant data.